Aplastic anemia

A Historic Downtown Oakland Hotel Re-Emerges as 130 Stylish Residences

Retrieved on: 
Martedì, Marzo 19, 2024
Mojave Desert, Jack London, Legislation, White Wolf Publishing, Partnership, Nike, Public policy, History, Policy, Entitlement, Jack London Square, Aplastic anemia, Housing, Olympic Games, Warrior, System, Palm, Interior design

OAKLAND, Calif., March 19, 2024 /PRNewswire/ -- Converting existing buildings into multifamily housing can be a significant step in alleviating California's housing crisis. In one prominent example, Riaz Capital's newly completed multifamily project, ArtHaus Jack London, has been refashioned from the former Z-Hotel, an Oakland icon. This stylish 130 residence project makes entry-level housing more affordable for city residents, while preserving a slice of history in Oakland's Jack London Square.

Key Points: 
  • In one prominent example, Riaz Capital's newly completed multifamily project, ArtHaus Jack London, has been refashioned from the former Z-Hotel, an Oakland icon.
  • This stylish 130 residence project makes entry-level housing more affordable for city residents, while preserving a slice of history in Oakland's Jack London Square.
  • It takes inspiration from the Saguaro Hotel in Palm Springs, whose color palette is derived from the flora of the Mojave Desert.
  • This law enabled us to increase the ArtHaus Jack London unit count from 102 hotel rooms to 130 entry-level apartments.

Injectable Hematology Growth Factors Report 2024 - Evolution in Therapeutic Care - ResearchAndMarkets.com

Retrieved on: 
Martedì, Febbraio 13, 2024
Pharmaceutical, Health, Medical Devices, Hormone, Economics, Safety, Hematology, Antibody, Anemia, Thrombocytopenia, Kidney disease, Aplastic anemia, Patient, Neutropenia, Vaccine

The "Injectable Hematology Growth Factors Report" has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Injectable Hematology Growth Factors Report" has been added to ResearchAndMarkets.com's offering.
  • This report is a comprehensive evaluation and analysis of the technology, products, and participants providing the driving force behind this evolving segment of the healthcare sector.
  • Provides detailed analysis of injectable hematology growth factors delivery and device strategies, and product development factors.
  • Analyzes therapeutic demand drivers and evaluates injectable drug products in a number of key therapeutic segments.

Telix Signs Agreement to Acquire QSAM Biosciences and Its Bone Cancer Targeting Platform

Retrieved on: 
Mercoledì, Febbraio 7, 2024
PRV, Steroid, Prostate cancer, COGS, Contingent value rights, TLX, Palliative care, Osteosarcoma, Patient, Safety, Nephrotoxicity, QSAM, FDA, Appendix, Sarcoma, Food, Term sheet, Brain, Disease, Pain management, Acquisition, Metastasis, Samarium, ODD, Radiopharmaceutical, Aplastic anemia, Glioma, ASX, Priority review, Medical imaging

MELBOURNE, Australia, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has entered into an agreement to acquire QSAM Biosciences, Inc. (U.S. OTC: QSAM) and its lead investigational drug Samarium-153-DOTMP (153Sm-DOTMP).

Key Points: 
  • MELBOURNE, Australia, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has entered into an agreement to acquire QSAM Biosciences, Inc. (U.S. OTC: QSAM) and its lead investigational drug Samarium-153-DOTMP (153Sm-DOTMP).
  • QSAM is a United States (U.S.) based company developing therapeutic radiopharmaceuticals for primary and metastatic bone cancer.
  • Telix believes that 153Sm-DOTMP may benefit patients with metastatic lung and breast cancer, where many patients develop brain and bone metastases, and disease management often focusses on quality-of-life palliative care.
  • Telix will issue ordinary shares to the stockholders of QSAM at closing within its Listing Rule 7.1 placement capacity as consideration for the acquisition.

Harmonic Discovery Announces Licensing Agreement with BioVentures and UCSF for FLT3 Mutated AML Development Program

Retrieved on: 
Martedì, Gennaio 30, 2024
Medicine, UCSF, Acute myeloid leukemia, MD, Pharmacology, University of Arkansas, IND, Patient, AML, FLT3, Laboratory, Patent, Doctor of Philosophy, University, Aplastic anemia, Pharmaceutical industry

The compound, named HD-10019, is currently in pre-clinical development and is expected to commence IND-enabling studies in late 2024.

Key Points: 
  • The compound, named HD-10019, is currently in pre-clinical development and is expected to commence IND-enabling studies in late 2024.
  • HD-10019 is a type II kinase inhibitor that was rationally designed to overcome tyrosine kinase domain resistance mutations in the FLT3 kinase and improve myelosuppression versus standard of care agents for FLT3 mutated AML.
  • "We are excited to work with BioVentures and UCSF and take a step forward in delivering a novel treatment to FLT3 mutated AML patients," said Rayees Rahman, PhD, CEO of Harmonic Discovery.
  • Wilson Sonsini Goodrich & Rosati served as legal advisor to Harmonic Discovery on matters relating to the Licensing Agreement and related corporate and patent strategy matters.

Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 Doses

Retrieved on: 
Giovedì, Gennaio 25, 2024
Capecitabine, Patient, Incidence, NGC, Doctor of Pharmacy, Breast cancer, Cancer, HFS, Safety, PCSA, FDA, Aplastic anemia, BID, Metabolism, Physician, Pharmaceutical industry

HANOVER, MD, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for more patients suffering from cancer, announces the successful completion of the safety tolerability evaluation in its Phase 1b trial of Next Generation Capecitabine (“NGC-Cap”). From the Phase 1b data, two dosage regimens have been selected for the Phase 2 trial. The Phase 2 trial will be in advanced or metastatic breast cancer given FDA’s agreement that the Phase 1b data can be used to support the design of the Phase 2 trial in breast cancer.

Key Points: 
  • From the Phase 1b data, two dosage regimens have been selected for the Phase 2 trial.
  • The Phase 2 trial will be in advanced or metastatic breast cancer given FDA’s agreement that the Phase 1b data can be used to support the design of the Phase 2 trial in breast cancer.
  • The NGC-Cap Phase 1b trial evaluated capecitabine doses from 75 mg once a day (QD) to 225 mg twice a day (BID).
  • Although the primary objective of the Phase 1b trial in patients with advanced gastrointestinal (GI) cancer was not to evaluate efficacy, the Phase 1b trial was designed to provide some preliminary data on efficacy.

Moleculin Announces 2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Phase 2B/3

Retrieved on: 
Mercoledì, Gennaio 24, 2024
Northwestern University, Neutrophil, Patient, Research, OS, Acute myeloid leukemia, Anthracycline, Culture, Survival, Mouse, CRS, Thrombocytopenia, Safety, Allergy, STS, GBM, PFS, Febrile neutropenia, Bone marrow, Cardiotoxicity, NIH, Glioblastoma, Brain, Zika virus, FDA, Virus, HIV, Aplastic anemia, National Institutes of Health, AML, Clinical trial, Bangladesh Technical Education Board, SARS-CoV-2, Pharmacokinetics, ITT, Pharmaceutical industry

"Over the course of 2023, we delivered on our promise for a year of important data from our Annamycin clinical development programs.

Key Points: 
  • "Over the course of 2023, we delivered on our promise for a year of important data from our Annamycin clinical development programs.
  • We are well-positioned to continue building upon our encouraging growing body of preliminary clinical data and transition to pivotal Phase 2B/3 clinical trials by year-end 2024.
  • With our recent financing in December 2023, we have extended our runway into the fourth quarter of 2024, as well.
  • WP1122 successfully completed a Phase 1 clinical trial, which established a recommended safe dose for future potential Phase 1B or Phase 2 clinical trials.

Avenacy Announces Launch of Melphalan Hydrochloride for Injection in the U.S. Market

Retrieved on: 
Martedì, Gennaio 16, 2024
Biotechnology, General Health, FDA, Health, Pharmaceutical, Entrepreneurship, Patient, Hospital, Temperature, Anaphylaxis, Food, Multiple myeloma, Chromosome, Human, Melphalan, Safety, Bone marrow, Boxed warning, Bleeding, Aplastic anemia, Infection, Abbreviated New Drug Application, Pharmaceutical industry

Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Melphalan Hydrochloride for Injection in the United States as a therapeutic equivalent generic for Alkeran® for Injection (melphalan hydrochloride) approved by the U.S. Food and Drug Administration.

Key Points: 
  • Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Melphalan Hydrochloride for Injection in the United States as a therapeutic equivalent generic for Alkeran® for Injection (melphalan hydrochloride) approved by the U.S. Food and Drug Administration.
  • Melphalan Hydrochloride for Injection is indicated for the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate.
  • Avenacy’s Melphalan Hydrochloride for Injection is available in a kit containing a 50mg vial of lyophilized active ingredient and a 10mL vial of sterile diluent for admixture.
  • “Melphalan Hydrochloride for Injection will feature our proprietary product packaging and labeling, supporting our commitment to championing reliability, safety, and convenience for our customers.

Syros Highlights Anticipated 2024 Milestones to Deliver on the Value of Tamibarotene

Retrieved on: 
Lunedì, Gennaio 8, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, RARA, Aplastic anemia, Bone marrow, New Drug Application, Syros, Azacitidine, Venetoclax, Patient, Acute myeloid leukemia, AML, Pharmaceutical industry

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today highlighted anticipated 2024 milestones to deliver on the value of tamibarotene.

Key Points: 
  • Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today highlighted anticipated 2024 milestones to deliver on the value of tamibarotene.
  • In addition, we closed an approximately $45.0 million equity financing, providing us additional capital to advance the development of tamibarotene.
  • By the middle of the fourth quarter of 2024, we expect to report pivotal data from the SELECT-MDS-1 Phase 3 clinical trial.
  • Syros is also evaluating tamibarotene in combination with venetoclax and azacitidine in newly diagnosed unfit AML patients with RARA overexpression.

Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024

Retrieved on: 
Giovedì, Gennaio 4, 2024
ATR, Aplastic anemia, IND, DDR, Principal, FDA, Spacecraft, Breast, WEE1, Data, APRE, PLK1, PLK, PLK2, Complex conjugate, HERG, Therapy, Pharmacokinetics, PLK3, Cancer, PARP, Prostate, Toxicity, Patient, Safety, Non-Euclidean geometry, ADC, NSCLC, History, Pharmaceutical industry

DOYLESTOWN, Pa., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today provided a corporate update highlighting recent developments and plans for advancement of its pipeline of DNA Damage Response (DDR) anti-cancer agents in 2024.

Key Points: 
  • DOYLESTOWN, Pa., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today provided a corporate update highlighting recent developments and plans for advancement of its pipeline of DNA Damage Response (DDR) anti-cancer agents in 2024.
  • The most recent analysis of the data cut (January 2, 2024) shows that two patients have achieved stable disease – one each in the 50 mg and 200 mg cohorts.
  • Upon the addition of the higher dose cohorts, Aprea expects to determine the recommended Phase 2 dose (RP2D) in the second half of 2024.
  • Aprea will be hosting institutional investor and business development meetings at the Annual Corporate Access Event in San Francisco, hosted by our investor relations firm LifeSci Partners.

Human medicines European public assessment report (EPAR): Hycamtin, topotecan, Date of authorisation: 12/11/1996, Revision: 39, Status: Authorised

Retrieved on: 
Martedì, Gennaio 2, 2024
Marketing, Constipation, INN, Leukopenia, Woman, Carcinoma, Lung cancer, Fatigue, Nausea, DNA, Cancer, Neoplasm, Infection, SCLC, Mouth ulcer, Risk management, Anatomy, Paclitaxel, IIA, CHMP, Diarrhea, Fever, ATC, Capsule, European, Disease, Weakness, Mucositis, Anemia, Medical Subject Headings, Febrile neutropenia, European Commission, Cyclophosphamide, Vincristine, International, Neutropenia, Somatic symptom disorder, Aplastic anemia, Language, Cisplatin, Thrombocytopenia, Medication, Select, Patient, Medicine, Vomiting, Ovary, Survival, Ovarian cancer, Cervical cancer, Hair loss, Radiation, Doxorubicin, Committee, Medical device

Human medicines European public assessment report (EPAR): Hycamtin, topotecan, Date of authorisation: 12/11/1996, Revision: 39, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Hycamtin, topotecan, Date of authorisation: 12/11/1996, Revision: 39, Status: Authorised